Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20059634 | 1.00 | PDE10A (0.84) | PDE10A | |
| SCHEMBL20059543 | 0.91 | PDE10A (1.00) | PDE10A | |
| SCHEMBL20059871 | 0.91 | PDE10A (1.00) | PDE10A | |
| SCHEMBL16092154 | 0.91 | PDE10A (1.00) | PDE10A | |
| SCHEMBL16050184 | 0.91 | PDE10A (1.00) | PDE10A | |
| SCHEMBL16092192 | 0.91 | PDE10A (0.82) | PDE10A | |
| SCHEMBL20059590 | 0.91 | PDE10A (1.00) | PDE10A | |
| SCHEMBL17439721 | 0.91 | PDE10A (1.00) | PDE10A | |
| SCHEMBL20059892 | 0.91 | PDE10A (0.82) | PDE10A | |
| SCHEMBL16092149 | 0.89 | PDE10A (1.00) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968324-B1 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-18 | — | — | EP | claimed |
| US-9353104-B2 | Substituted pyridizinone derivatives as PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | claimed |
| US-20160016947-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | claimed |
| EP-2968324-B1 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2968324-B1 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9353104-B2 | Substituted pyridizinone derivatives as PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353104-B2 | Substituted pyridizinone derivatives as PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353104-B2 | Substituted pyridizinone derivatives as PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160016947-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016947-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016947-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2014150114-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014139150-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016947-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | PDE12, PDE5A, PDE10A | PDE10A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.